Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public/Private Cooperation, Tailored Assistance Deemed Key To Enhancing Quality Of US Drug Imports

Executive Summary

Public health experts tell committee that much work lies ahead in strengthening the regulatory systems of low-and middle-income countries, and recommend ways to bolster these systems and improve the quality of imports.

You may also be interested in...



WHO Regulatory Agency Benchmarking System Set For Early 2019 Launch

The WHO is planning to introduce a new version of its tool for evaluating the “maturity level” of national drug regulatory agencies across the world as part of a drive to strengthen regulatory systems and make them more effective and transparent. It is also introducing the concept of "WHO-listed authority".

Signs Of Improving FDA Inspection Outcomes At Indian Sites But Long Road Ahead

Moving up the manufacturing compliance curve is still a work in progress for several Indian firms, but there appear to be some early signs that US FDA inspection outcomes, in general, may have improved.

IOM Pushes For FDA Collaboration With Foreign Regulators

In a report on how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad, the Institute of Medicine recommends the agency provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel